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In the  near  future  oral  polio  vaccine  (OPV)  will  be  replaced  by  inactivated  polio  vaccine  (IPV)  as part  of
the  eradication  program  of  polio.  For  that  reason,  there  is a  need  for  substantial  amount  of  safe  and  more
affordable  IPV for low-income  countries.  Bioneedles,  which  are  biodegradable  mini-implants,  have  the
potential  to deliver  vaccines  outside  the  cold-chain  and  administer  them  without  the  use  of  needles  and
syringes.  In  the  current  study,  Bioneedles  were  ﬁlled  with  IPV,  subsequently  lyophilized,  and  antigenic
recoveries  were  determined  both  directly  after  IPV-Bioneedle  preparation  as  well  as  after  elevated  sta-
bility testing.  Further,  we  assessed  the  immunogenicity  of IPV-Bioneedles  in  rats  and  the  residence  time
at  the  site of administration.
Trivalent  IPV  was formulated  in Bioneedles  with  recoveries  of  101  ±  10%,  113 ±  18%, and  92 ±  15%,
respectively  for  serotypes  1, 2 and  3. IPV  in  Bioneedles  is  more  resistant  to elevated  temperatures  than
liquid  IPV:  liquid  IPV retained  less  than  half  of  its antigenicity  after  1 day  at 45 ◦C and  IPV  in Bioneedles
showed  remaining  recoveries  of 80 ±  10%,  85 ±  4% and 63  ± 4% for the  three  serotypes.  In vivo imaging
revealed  that  IPV  administered  via  Bioneedles  as  well  as  subcutaneously  injected  liquid IPV  showed  a
retention  time  of 3  days  at the site  of  administration.  Finally,  an immunogenicity  study  showed  that
IPV-ﬁlled  Bioneedles  are  able  to induce  virus-neutralizing  antibody  titers  similar  to those  obtained  by
liquid intramuscular  injection  when  administered  in  a  booster  regime.  The  addition  of LPS-derivate  PagL
in IPV-ﬁlled  Bioneedles  did  not  increase  immunogenicity  compared  to IPV-Bioneedles  without  adjuvant.
The current  study  demonstrates  the pre-clinical  proof  of  concept  of IPV-ﬁlled  Bioneedles  as  a  syringe-
free  alternative  delivery  system.  Further  pre-clinical  and  clinical  studies  will  be required  to  assess  the
feasibility  whether  IPV-Bioneedles  show  sufﬁcient  safety  and  efﬁcacy,  and may  contribute  to the  efforts
to eradicate  and  prevent  polio  in the  future.
ublis© 2015  The  Authors.  P
. Introduction
Poliomyelitis is caused by any one of the three serotypes of
oliovirus (type 1, type 2 or type 3) that can be prevented through
accination. Since the launch of the Global Polio Eradication Ini-
iative (GPEI) in 1988, the global incidence of polio has reduced
y more than 99% and the number of countries with endemic
olio has decreased from 125 to 3. While the live attenuated oral
olio vaccine (OPV) is currently the vaccine of choice in develop-
ng countries, it is associated with safety concerns, i.e., reversion
f the vaccine virus to a form that causes paralysis and the risk of
∗ Corresponding author at: Intravacc, Antonie van Leeuwenhoeklaan 9, P.O. Box
50, 3720 AL Bilthoven, The Netherlands. Tel.: +31 (0)30 274 2314.
E-mail address: heleen.kraan@intravacc.nl (H. Kraan).
ttp://dx.doi.org/10.1016/j.vaccine.2015.03.011
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
circulating vaccine-derived polioviruses (cVDPVs) [1]. Therefore,
replacement of OPV by inactivated polio vaccine (IPV) is the new
strategy striving toward global polio eradication. The cost increase
is a main issue in replacing OPV with the more expensive IPV. In
this context, adjuvants, like the lipopolysaccharide (LPS) derivate
PagL, were shown to have dose-sparing capacity for IPV prepared
from attenuated Sabin strains [2].
Alternative delivery technologies, via the skin [3,4] or mucosal
sites [5,6] might further beneﬁt the administration of IPV in the
ﬁeld if they are at least non-inferior in human. These delivery tech-
nologies can have advantages, such as easy and fast administration,
minimizing/eliminating the risk on needle-stick injuries or reuse
of needles and/or minimal generation of waste [7,8]. Among the
alternative delivery technologies that might be used for IPV is the
Bioneedle technology, which allows parenteral vaccine adminis-
tration without the use of needle and syringe. Bioneedles are small
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ollow mini-implants from biodegradable polymers that can be
lled with antigen followed by a lyophilization process. After sub-
utaneous delivery, the implant dissolves and thereby releases the
ntigen. Pre-clinical data with different antigens showed the feasi-
ility of Bioneedles as vaccine delivery system [9–12]. A ﬁrst phase
 clinical study with solid Bioneedles (without antigen) revealed
ood tolerability [13]. Besides, if formulated properly, vaccines in
ioneedles are thermostable, which can diminish the dependence
n the cold-chain [10–12].
Recently, we have developed a formulation that stabilizes IPV
uring lyophilization and subsequent storage at higher tempera-
ures [14]. The aim of current study is to develop a syringe-free
dministered polio vaccine by using the Bioneedle technology.
herefore, Bioneedles containing lyophilized IPV were developed,
hermostability was assessed by D-antigen ELISA, and the immuno-
enicity in rats was evaluated by determining virus-neutralizing
VN) antibody titers. To investigate whether the immune response
licited by IPV-ﬁlled Bioneedles could be increased by using an
djuvant, a formulation containing the LPS-derivate PagL was
ncluded in this study. As the kinetics at the site of administration
f a dry, encapsulated vaccine may  be different compared to ﬂuid
njection, we performed a real-time in vivo imaging study.
. Materials and methods
.1. Materials
The IPV used in this study is a ten times concentrated trivalent
ulk at a nominal D-antigen content (expressed in D units, DU) of
00–80–320 DU/mL (for types 1, 2 and 3 respectively, Salk strains)
nd routinely produced by the Netherlands Vaccine Institute as
escribed previously [15].
d-Sorbitol, monosodium glutamate and magnesium chlo-
ide hexahydrate were from Sigma (St. Louis, MO). Citric acid
Sigma–Aldrich, St. Louis, MO)  and Na2HPO4 (Fluka, Buchs,
witzerland) were used to prepare McIlvaine buffer. All excipients
sed were of reagent quality or higher grade. IRDye800CW® pro-
ein labeling kit used for the in vivo imaging study was  obtained
rom LI-COR Biosciences (Lincoln, NE). The adjuvant PagL LPS is
btained through expression of the Bordetella bronchiseptica PagL
ene in Neisseria meningitides LPS as described by Arenas et al. [16].
.2. Methods
.2.1. IPV-Bioneedle production
Trivalent IPV bulk was concentrated using 10 kDa Amicon Ultra
entrifugal ﬁlters (Merck Millipore, Billerica, MA)  and formulated
ith 8% (w/v) sorbitol, 5% (w/v) monosodium glutamate and 5%
w/v) magnesium chloride in McIlvaine buffer (10 mM,  pH 7.0). For
he imaging experiment, IPV was labeled with ﬂuorescent probe
RDye800 CW® according to the accompanying instructions.
Empty Bioneedles (0.9 mm × 12 mm,  made of extruded starch
17]) were obtained from the Bioneedle Technologies Group and
lled with 5 L of the liquid IPV formulation (with or without adju-
ant) using a specially designed ﬁlling apparatus and immediately
rozen on a plate at −50 ◦C. Subsequently, Bioneedles were loaded
n a Zirbus freeze-drying unit sublimator 2–3–3 with pre-cooled
helves at −50 ◦C. The lyophilization process was based on a process
sed for IPV in vials [14]. In brief, primary drying was  performed at
45 ◦C (0.045 mbar) and secondary drying by further increasing the
helf temperature to 25 ◦C followed by a 24 h drying step at 25 ◦C
0.01 mbar). The lyophilized Bioneedles were individually stored in
ials, closed under vacuum and sealed with alu-caps.
D-antigen content of the Bioneedles directly after lyophilization
nd during stability testing at 45 ◦C for 4 weeks and at 60 ◦C for 1 (2015) 2030–2037 2031
week, was determined by a sandwich ELISA as described previously
[18]. DU recovery was expressed relative to the liquid formulation
prior to lyophilization.
2.2.2. In vivo ﬂuorescence imaging
Animal experiments were conducted in accordance with the
guidelines provided by the Dutch Animal Protection Act, and
were approved by the Committee for Animal Experimentation of
Intravacc. Female CD Hairless rats (Crl:CD-Prsshr8, Charles River,
Sulzfeld, Germany) received IRDye800CW®-labeled trivalent IPV
(40–8–32 DU per dose) via subcutaneous liquid injection (0.1 mL
per dose) or Bioneedle administration using a sterilized trocar with
mandrin as described previously (5 animals/group, unless other
stated) [11]. Scans of animals, positioned in dorsal recumbence,
were performed eight times during 72 h after immunization under
2% isoﬂuran/O2 anesthesia using an IVIS Spectrum imaging system
(PerkinElmer, Waltham, MA). The threshold was  set using a back-
ground scan made prior to immunization. The imaging sequences
were 760, 780, 800, 820 and 840 nm for emission and 710 nm as
excitation. Spectral unmixing was performed to decompose the
emitted light into autoﬂuorescence and label-speciﬁc ﬂuorescence.
The data represent the quantity of the ﬂuorophore at each pixel.
Data was analyzed using the Living Imaging software 4.1 from
PerkinElmer and GraphPad Prism 6.4 software. The relative ﬂuo-
rescence intensity (percentage of initial ﬂuorescence) at the site of
administration was calculated for each animal.
2.2.3. Immunization study
Outbred Wistar rats (HsdCpb:WU, Harlan Laboratories,
The Netherlands) received trivalent IPV (2.7–0.6–2.1 DU/dose,
10 animals/group) with or without PagL LPS (1 g/dose). Liquid
formulations were administered intramuscularly (i.m.) or subcu-
taneously (s.c.) by injection in the hind limb or neck between the
ears, respectively, and Bioneedles were implanted as described
above. All immunizations were performed under isoﬂuran/O2
anesthesia. Vaccinations were given on days 0 (prime) and 28
(boost), and sera collected prior to immunization on day 0, on
day 21 and on day 49. On day 49, animals were sacriﬁced under
anesthesia by bleeding (heart puncture).
Serum polio-speciﬁc IgG and virus neutralizing (VN) antibodies
against all three poliovirus serotypes were determined as described
earlier [2]. Baseline VN titers reported are based on four animals
receiving mock vaccine as negative control.
2.2.4. Statistical analysis
For comparative analysis of immunogenicity, data were
tested by one-way analysis of variance (ANOVA) followed by a
Tukey–Kramer test for multiple comparisons. Probability (p) val-
ues <0.05 were considered signiﬁcant. All statistical analyses were
performed using GraphPad Prism version 6.0 (GraphPad Software
Inc., La Jolla, CA).
3. Results
3.1. IPV-Bioneedle: process and product stability
Bioneedles were ﬁlled with a trivalent IPV formulation con-
taining excipients that are known to stabilize the antigen during
lyophilization and subsequent storage. Directly after lyophilization,
the D-antigen content was determined by dissolving Bioneedles,
followed by a D-antigen ELISA. DU recoveries were 101 ± 10%,
113 ± 18% and 92 ± 15%, respectively for types 1, 2 and 3 (n = 3).Product stability was  evaluated by incubating Bioneedles for up
to 1 month at 45 ◦C or 1 week at 60 ◦C. Subsequently, DU recov-
ery was  determined and compared to the liquid IPV stored at the
same conditions (Fig. 1). Liquid IPV stored for 24 h at 45 ◦C showed
2032 H. Kraan et al. / Vaccine 33 (2015) 2030–2037
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Big. 1. Thermostability of IPV Bioneedles. Liquid IPV formulations and IPV-ﬁlled 
-antigen content (DU recovery) was determined by ELISA. Bars represent mean DU
ecoveries of 10 ± 2%, 47 ± 0% and 18 ± 5% for types 1, 2 and 3,
espectively, whereas the IPV Bioneedle maintained its D-antigen
ontent at respectively 80 ± 10%, 85 ± 4% and 63 ± 4% (Fig. 1A). One-
eek storage of the liquid IPV formulation at 45 ◦C resulted in
omplete loss of type 1 D-antigenicity and 80% loss of types 2 and
. After 4 weeks also types 2 and 3 were not detectable anymore. In
ontrast, Bioneedles showed about 60% type 1 recovery and com-
lete type 2 recovery and about 50% type 3 recovery after 1 week
5 ◦C. After 4 weeks at 45 ◦C DU recoveries were 27 ± 10% for type
, 64 ± 15% for type 2, and 18 ± 13% for type 3. IPV Bioneedles con-
aining the PagL adjuvant were also subjected to stability studies
nd showed DU recoveries that were comparable to those of IPV
ioneedles without PagL (data not shown).edles were incubated at 45 ◦C (A) and 60 ◦C (B). Subsequently, for each serotype
veries ± SD (n = 3) normalized for the DU recovery directly after lyophilization.
At 60 ◦C, the liquid formulation showed complete loss of D-
antigenicity after 15 min, whereas no loss in DU recovery for type
1 was observed in IPV-ﬁlled Bioneedles and remaining recoveries
of 73 ± 6% for type 2 and 81 ± 5% for 3 were found (Fig. 1B). Upon
storage for a longer period at 60 ◦C, D-antigen content decreased
dramatically showing highest loss for serotypes 1 and 3. After 1
week at 60 ◦C, the Bioneedles did not contain any D-antigen any-
more.
In order to test whether the formulations used in this study
were able to resist real-life, unrefrigerated and thus varying con-
ditions, liquid IPV and IPV-Bioneedles were taken on a 3-week trip
through Middle Eastern countries. Temperature was tracked during
those weeks and DU content was determined afterwards (Fig. 2B).
H. Kraan et al. / Vaccine 33 (2015) 2030–2037 2033
Fig. 2. Stability of IPV-Bioneedles outside the cold-chain. Liquid IPV formulations and IPV-ﬁlled Bioneedles were taken on a travel through Mideast Asia countries. Temperature
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was  logged for 3 weeks (A) and, subsequently, D-antigen content (DU recovery) was
he  DU recovery directly after lyophilization.
he average temperature was determined at 26.0 ◦C with a mini-
um  of 17.0 ◦C and a maximum of 46.5 ◦C. During the trip, the IPV
ioneedles and liquid IPV were four times exposed to a temperature
bove 40 ◦C (Fig. 2A). For types 2 and 3, DU recoveries of 70–80%
ere found for both the liquid and Bioneedle formulations. How-
ver, whereas liquid IPV did not contain type 1 D-antigen, 100% DU
ecovery was observed in the IPV Bioneedle (Fig. 2B).
.2. Biodistribution study
To determine the kinetics of the antigen release from the Bionee-
le and removal from the injection site, a real-time in vivo imaging
tudy was performed over the course of time post-inoculation.
ithin 5 h after administration, the ﬂuorescent signal from a
ioneedle ﬁlled with free IR-dye (not linked to IPV) decreased
o background level (Fig. 3B). Labeled IPV was  removed from the
njection site considerably slower than free dye irrespective of the
dministration method (injection or Bioneedle). Surprisingly, IPV
n Bioneedles disappeared with the same kinetics as ﬂuid injection.
t 72 h post-immunization, labeled IPV was not detectable at the
ite of administration.
.3. Immunization study
Wistar rats were immunized with IPV, delivered via either
ioneedles or liquid injection, in a prime-booster regime. Subse-
uently, immune responses elicited by IPV-ﬁlled Bioneedles were
ompared with those obtained via liquid injection.
After prime immunization, rats that received i.m. liquid injec-
ion showed low VN titers and only two of them elicited a detectable
esponse against type 1 (Fig. 4A), whereas all animals showed
 VN titer against type 2 following i.m. immunization with IPV
Fig. 4B). Rats receiving a prime immunization with an IPV-ﬁlled
ioneedle showed VN titers for types 1 and 2 that were similar to
hose obtained with i.m. liquid injection using syringe and needle.
lthough prime immunization with an IPV-containing Bioneedle
nduced signiﬁcant lower VN titers for type 3 compared to i.m.
iquid injection (p < 0.01), it induced similar VN type 3 titers com-
ared to s.c. liquid injection (Fig. 4C). In general, higher numbers
f responders were observed in the groups immunized with IPV in
he presence of PagL LPS (Fig. 4A–C). These responses were only
igniﬁcantly higher after the boost immunization for types 1 and 2.
VN titers in rats were comparable for all serotypes after booster
mmunization via either IPV-ﬁlled Bioneedles or i.m. IPV injection
Fig. 4D–F). The route of administration had no effect on the induc-
ion of VN antibodies after booster immunization. The addition of
agL LPS showed signiﬁcant improved VN titers for types 1 and 2
hen administered via i.m. injection (Fig. 4D and E). Serum IgGmined by ELISA (B). Bars represent mean DU recoveries ± SD (n = 3) normalized for
titers, which were determined by ELISA, showed similar results for
all serotypes compared with the VN titers (data not shown).
4. Discussion and conclusions
Current proof of concept study demonstrated the potential
of an alternative delivered IPV using the Bioneedle technology.
Compared with liquid IPV, IPV formulated in Bioneedles showed
improved thermostability and similar kinetics at the site of injec-
tion as well as comparable immunogenicity when administered in
a booster regime. Whereas improved immunogenicity was gener-
ated by addition of PagL to liquid IPV, immune responses elicited
by IPV-Bioneedles were not potentiated by PagL.
The lyophilization step needed during the production of
vaccine-ﬁlled Bioneedles is an important characteristic of the
Bioneedle technology that might make it an interesting vaccine
delivery approach without dependence on the cold-chain [10–12].
However, lyophilization of polio vaccines while maintaining their
functionality showed to be challenging [19]. Excipients are required
to protect the antigen against freezing and drying stresses that
occur during the lyophilization process. For production of Bionee-
dles containing vaccine formulations in general, the disaccharide
trehalose (5% w/v) was able to fully protect tetanus toxoid [10],
hepatitis B surface antigen [11] and the inﬂuenza hemagglu-
tinin antigen (HA) during lyophilization [12]. Nevertheless, even
10% (w/v) trehalose or sucrose was  not enough to maintain the
D-antigen content of IPV during the freezing and subsequent
drying steps [14]. The formulation used in IPV-Bioneedles was
inferred from an earlier study where a combination of sorbitol,
monosodium glutamate (MSG) and magnesium chloride (MgCl2)
was able to protect IPV during lyophilization and storage [14].
In order to obtain an appropriate viscosity for the use in Bionee-
dles, it was required to use the reported optimized formulation
at lower amounts of the same excipients (8–5–5% instead of
10–8.5–8.5% sorbitol, MSG  and MgCl2, respectively) [14]. This for-
mulation yielded similar D-antigen recoveries as compared with
the optimal formulation in vials as described in the lyophilization
study [14].
At temperatures above 56 ◦C, within minutes poliovirus and vac-
cine are converted to C-antigen [20], which are not able to induce
VN antibodies [21]. Therefore, accelerated stability was determined
above and below this threshold: 45 ◦C and 60 ◦C. The lyophilized
formulation used in this study was slightly less stable when com-
pared to the optimal formulation in vials, both in Bioneedles and
vials [14]. In contrast, whereas the lyophilized IPV formulation in
vials maintained type 1 antigenicity after a 1-week incubation at
45 ◦C [14], a signiﬁcant loss in type 1 D-antigen was observed for
the same formulation in Bioneedles. The optimized formulation
2034 H. Kraan et al. / Vaccine 33 (2015) 2030–2037
Fig. 3. Kinetics of the antigen at the site of administration following IPV immunization either via liquid injection or Bioneedle insertion. Whole-body ﬂuorescence images
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ree  IR dye. Depicted animals were representative for the whole group (A). The relat
eans ± SD from ﬁve animals (except for BN free dye group where only two  anima
n vials had a residual moisture content above 3%, the Euro-
ean Pharmacopeia limit [14]. Unfortunately, we were not able to
easure the water content in Bioneedles due to interference of the
ioneedle-material with the assay. Since this formulation was less
table than the optimized lyophilized IPV formulation (in vials),
e expect a higher residual moisture content for lyophilized IPV
n Bioneedles, potentially resulting in the observed decrease in
hermostability when compared to lyophilized IPV in vials. Nev-
rtheless, the lyophilized IPV formulated in Bioneedles was more
hermostable than the liquid IPV for all serotypes. Optimization of
he IPV-Bioneedle formulation and lyophilization process, e.g., by
rolongation of the secondary drying step and thereby reducing
he residual moisture content, could probably further increase the
tability of IPV-ﬁlled Bioneedles.Earlier, it was suggested that Bioneedles might induce a short-
erm ‘depot effect’ or alter the kinetics of antigen recognition and
rocessing, which could explain the enhanced immunogenicity
f Bioneedles for some antigens [10,12]. Some vaccine deliveryid injection with labeled IPV or Bioneedle (BN) insertion with either labeled IPV or
orescence intensity at the site of administration was quantiﬁed (B). Data represent
e used).
systems are able to prolong the localization period of the anti-
gen at the site of injection, thereby slowly releasing the antigens
at the injection site for a period of up to more than 1 week
[22]. An in vivo imaging study was  performed using infrared-dye
labeled IPV to investigate whether the residence time at and release
from the administration site was different between IPV formu-
lated in Bioneedles and subcutaneously injected liquid IPV. Both
administration methods (Bioneedle and liquid injection) showed a
comparable release from the injection site and a similar distribution
pattern over time. Within a few days, the labeled IPV in Bioneedles
completely disappeared from the site of administration showing
comparable clearance as subcutaneously injected ovalbumin alone
in mice [23]. This demonstrated that Bioneedles did not form a
depot (at least for IPV and the formulation used) at the site of
injection and supports the fact that in general the immunogenic-
ity of Bioneedle formulated antigens seemed to be comparable
to injected ﬂuid vaccine, which is an advantage in the licensing
process.
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Fig. 4. Mean virus neutralizing (VN) antibody titers in serum. Rats (n = 10) received IPV in the absence (closed symbols) or the presence of PagL LPS (open symbols) as adjuvant.
Four  animals received mock vaccine as negative control and are the source of the baseline VN titers. Immunizations were given via intramuscular (i.m.) or subcutaneous (s.c.)
liquid  injection or via subcutaneous Bioneedle insertion and the neutralizing capacity of serum antibodies was determined 3 weeks after prime (day 21, A–C) or 3 weeks after
booster immunization (day 49, D–F). Two animals died unexpectedly during the experiment, which was unrelated to immunization. Asterisks indicate signiﬁcant differences
between groups (*p < 0.01, **p < 0.001).
2 ine 33
s
p
p
t
t
m
n
i
o
a
o
i
i
q
B
a
i
t
w
i
a
f
b
d
e
d
a
e
h
d
i
P
w
B
t
h
a
b
s
s
f
a
n
A
P
I
i
B
p
d
u
T
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[036 H. Kraan et al. / Vacc
Immunogenicity of IPV Bioneedles was evaluated in rats mea-
uring VN capacity of serum, which is a surrogate marker for
rotection [24]. A booster regime seemed to be essential for a
roper immune response similar to that induced by IPV injection in
he rat model. The observed low VN titers after prime immuniza-
ion were not surprising, since other IPV formulations showed also
oderate immunogenicity, as indicated by low VN titers and low
umbers of responders following a single vaccination (i.m.) [2,25].
In order to increase the immunogenicity of IPV, PagL was
ncluded as adjuvant. Several studies have shown the potential
f dose sparing by using adjuvants for IPV based on Salk [25–28]
nd Sabin strains [2,29]. PagL LPS is able to enhance the potency
f Sabin IPV after both prime and booster immunization (via the
.m. route), serotype 3 being most immunogenic [2]. Since type 3
s the most vulnerable serotype during lyophilization and subse-
uent storage of dried IPV [14], it was decided to include PagL in
ioneedles to compensate for possible loss of immunogenicity. The
ddition of PagL in the lyophilized IPV-Bioneedles did not result in
mproved VN titers at the dose evaluated. However, PagL was able
o enhance the immune response against the poliovirus serotypes
hen administered via liquid injection (36-, 10-, 8-fold VN titer-
ncrease for types 1, 2 and 3, respectively), albeit to a lesser extent
s observed for Sabin IPV in a booster-regime (294-, 578- and 2352-
old for types 1, 2 and 3, respectively) [2]. The lack of comparability
etween wild type (Salk) IPV and Sabin IPV, which is due to their
ifferent antigenic and immunogenic properties, has been reported
xtensively [30–32]. The lack of adjuvant activity in the Bionee-
le material may  be the result of interaction between adjuvant
nd Bioneedle. However, another LPS-derivate, LpxL1, was  able to
nhance the immunogenicity of Bioneedles in combination with
epatitis B vaccine in mice [11]. Further investigation on the PagL
ose, kinetics and routing upon delivery is needed (e.g., by in vivo
maging). In the study reported here signiﬁcant adjuvant effects of
agL included in IPV Bioneedles, at least for the evaluated dose,
ere not seen.
This study demonstrated the pre-clinical proof of concept of
ioneedles for IPV. When formulated in Bioneedles, IPV was more
hermostable as compared with the liquid IPV. A clinical study in
ealthy volunteers showed already that solid Bioneedles without
ny antigen were well tolerated [13]. However, several steps should
e taken in the further development of this alternative delivery
ystem for polio vaccination, including toxicity and dose ﬁnding
tudies. Those (pre-) clinical studies, using an approved applicator
or Bioneedle administration, should prove the practical use, safety,
nd efﬁcacy of Bioneedles for human vaccination, and their useful-
ess to strive for polio eradication and in the period thereafter.
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